Plasmid DNA (pDNA) production is a cornerstone of modern biotechnology, enabling breakthroughs in mRNA vaccines and gene therapies. However, current production is monopolised by Escherichia coli, a versatile but ageing workhorse with limitations in efficiency and adaptability. This consortium aims to challenge this monopoly by exploring the untapped potential of Vibrio natriegens, a fast-growing, non-pathogenic bacterium with almost twice the growth rate of E. coli.

The project will focus on optimising V. natriegens for efficient pDNA production, addressing diverse plasmid requirements and paving the way for more sustainable and flexible biotechnological processes. If successful, V. natriegens could transform the field and provide a robust alternative for industries that rely on pDNA, from healthcare to synthetic biology.

This collaboration underlines TU Darmstadt's commitment to driving innovation in the global bioeconomy and fostering international scientific partnerships.